Brokerages expect LivaNova PLC (NASDAQ:LIVN) to post earnings of $0.97 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for LivaNova’s earnings. The lowest EPS estimate is $0.96 and the highest is $0.97. LivaNova reported earnings per share of $1.12 during the same quarter last year, which suggests a negative year-over-year growth rate of 13.4%. The firm is expected to report its next earnings report on Wednesday, February 26th.
On average, analysts expect that LivaNova will report full-year earnings of $3.05 per share for the current year. For the next year, analysts expect that the business will report earnings of $3.31 per share, with EPS estimates ranging from $3.30 to $3.33. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow LivaNova.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.09. The company had revenue of $268.60 million for the quarter, compared to analysts’ expectations of $273.41 million. LivaNova had a positive return on equity of 9.44% and a negative net margin of 20.35%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 earnings per share.
Several equities research analysts recently issued reports on LIVN shares. Piper Jaffray Companies set a $90.00 price objective on shares of LivaNova and gave the company a “buy” rating in a research note on Friday, September 6th. Needham & Company LLC reduced their price objective on shares of LivaNova from $91.00 to $88.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. Zacks Investment Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. ValuEngine raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, BidaskClub raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $97.67.
Shares of NASDAQ LIVN traded up $1.24 during trading on Friday, hitting $78.26. The company had a trading volume of 186,100 shares, compared to its average volume of 382,640. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.81 and a current ratio of 1.17. LivaNova has a 52 week low of $64.80 and a 52 week high of $126.99. The business’s 50-day moving average is $73.01 and its 200 day moving average is $74.54. The company has a market cap of $3.73 billion, a P/E ratio of 24.69, a PEG ratio of 3.51 and a beta of 0.53.
In other LivaNova news, CEO Damien Mcdonald sold 1,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $73.82, for a total transaction of $73,820.00. Also, Director Daniel Jeffrey Moore sold 1,500 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $80.25, for a total transaction of $120,375.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,000 shares of company stock valued at $471,735. 0.41% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in LIVN. Invesco Ltd. lifted its position in LivaNova by 376.8% during the 2nd quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock worth $165,437,000 after acquiring an additional 1,816,788 shares during the last quarter. Paradice Investment Management LLC lifted its position in LivaNova by 720.1% during the 3rd quarter. Paradice Investment Management LLC now owns 469,807 shares of the company’s stock worth $34,667,000 after acquiring an additional 412,521 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in LivaNova by 18.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock worth $172,349,000 after acquiring an additional 378,564 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in LivaNova by 1,661.4% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 392,149 shares of the company’s stock worth $28,219,000 after acquiring an additional 369,885 shares during the last quarter. Finally, Primecap Management Co. CA lifted its position in LivaNova by 148.8% during the 2nd quarter. Primecap Management Co. CA now owns 475,220 shares of the company’s stock worth $34,197,000 after acquiring an additional 284,220 shares during the last quarter. 89.74% of the stock is owned by hedge funds and other institutional investors.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Recommended Story: 52-week highs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.